GALWAY, Ireland & SAN DIEGO, Calif.--(BUSINESS WIRE)--ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has been awarded an Innovation ...

Jaime Onk joined the firm in 2002 and has more than 16 years of experience in working with both publicly-traded and privately-held companies. Onk specializes in the audit of employee benefit plans, ...

GALWAY, Ireland & SAN DIEGO--(BUSINESS WIRE)--ONK Therapeutics Ltd, an innovative cell therapy company focused on engineered natural killer (NK) cell therapies, today announced it has entered into ...

ONK is also developing ONKT104, a dual-targeted CAR-NK product targeting CLEC12A (also known as CLL-1) utilising a humanised ScFv. CLEC12A is strongly expressed by blasts in the majority of acute ...

Intellia Therapeutics, Inc. NTLA announced that it has entered into a licensing and collaboration agreement with a privately-held company, ONK Therapeutics, Inc., to develop new therapies for the ...

Intellia is on a deal spree. The first-in-human gene editing biotech will receive up to $920 million from ONK Therapeutics in a collaboration agreement focused on CRISPR-edited natural killer cell ...

Chris Nowers has joined natural killer (NK) cell therapy startup ONK Therapeutics as CEO. ONK disclosed the appointment of Nowers, the former head of Kite Pharma’s European operation ...

ONK will receive non-exclusive rights to Intellia’s proprietary ex-vivo CRISPR/Cas9 technology in the development of five allogeneic NK cell therapies. Intellia Therapeutics, a gene-editing company, ...

ONK has developed a process that genetically engineers natural killer cells to allow them to better pursue cancer cells that have made themselves invisible to normal natural killer (NK) cells. It ...

Serial life sciences entrepreneur Seamus Mulligan has invested in Galway company ONK Therapeutics for the second time this year alongside American biotech investor Acorn Bioventures and other ...